Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMG-7289 in Essential Thrombocythemia and Polycythemia Vera
NCT04262141Phase 2Active, not recruiting
- Start
- Oct 2020
- Primary completion
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bomedemstat in essential thrombocythemia (ET) and polycythemia vera (PV). Primary endpoint: Hematologic Response Rates at 24 weeks. Started Oct 2020; status: active, not recruiting.
02
Drugs
bomedemstat
03
Conditions
essential thrombocythemia (ET)polycythemia vera (PV)
Beyond the preview
Go deeper on NCT04262141.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04262141.